Dihexa: The HGF/MET-Potentiating Nootropic Peptide Research Guide

What Is Dihexa?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from Angiotensin IV, a fragment of the renin-angiotensin system. It was developed at Washington State University by Joseph Harding and colleagues as part of a research program into cognitive enhancement and neurodegenerative disease treatment. Dihexa binds to hepatocyte growth factor (HGF) and potentiates its action at the MET receptor — a pathway with significant roles in neuronal survival, synaptogenesis, and memory consolidation.

What made Dihexa notable in preclinical literature is the scale of its reported potency: in some animal paradigms, it outperformed brain-derived neurotrophic factor (BDNF) by roughly seven orders of magnitude in synaptogenic activity. No human clinical trials have been completed, and Dihexa remains a research compound with no approved therapeutic applications.

Molecular Profile

Mechanism of Action

Dihexa's proposed mechanism centres on the HGF/MET signalling axis. HGF is a pleiotropic growth factor that, when it binds the MET receptor tyrosine kinase, triggers downstream cascades involved in cell survival, proliferation, and — in the CNS — dendrite branching and synapse formation.

Dihexa does not activate MET directly. Instead, it binds HGF with high affinity and appears to stabilise its active conformation, enhancing HGF's ability to dimerize the MET receptor and sustain downstream signalling. Harding's group reported that Dihexa had a binding affinity for HGF in the low femtomolar range in cell-based assays, though these measurements reflect competitive binding rather than direct functional potency and should be interpreted cautiously.

Key downstream effects documented in preclinical research:

• Synaptogenesis: Increased dendritic spine density and new synapse formation in hippocampal neurons in vitro.
• Neurogenesis: Some evidence of increased new neuron survival in the dentate gyrus of rodent models.
• Memory consolidation: Enhanced performance on spatial and associative memory tasks (Morris water maze, novel object recognition) in aged or cognitively impaired rodents.
• Neuroprotection: Reduced neuronal apoptosis markers in models of ischemia and induced neurodegeneration.

Dihexa also interacts with the AT4 receptor, also called IRAP (insulin-regulated aminopeptidase), which modulates memory encoding and is part of the broader angiotensin IV research lineage from which Dihexa descends. Whether the AT4 interaction contributes meaningfully to its cognitive effects is not resolved.

What the Research Actually Shows

Synaptogenic Potency Claims

The headline claim from Washington State University research (McCoy et al., 2013, Journal of Pharmacology and Experimental Therapeutics) was that Dihexa was "10 million times more potent than BDNF" at inducing synaptogenesis in hippocampal cultures. This figure has been widely cited in peptide research communities and is technically grounded in the published data, but several important caveats apply:

• The comparison was made against exogenous BDNF applied in culture — not endogenous BDNF signalling, which operates across orders-of-magnitude lower concentrations.
• In vitro potency ratios do not translate reliably to in vivo efficacy or therapeutic utility.
• The assay was proprietary to the Harding lab; independent replications in peer-reviewed literature remain limited.

That said, the underlying mechanism (HGF/MET modulation driving dendritic growth) is biologically plausible and aligns with the broader neurotrophic factor research field.

Cognitive Effects in Animal Models

Multiple rodent studies from the WSU group showed cognitive improvements in aged animals and in models of induced cognitive impairment:

• Aged rats given subcutaneous Dihexa showed significantly improved performance in the Morris water maze compared to vehicle controls, with effects described as comparable to those in younger animals.
• Scopolamine-impaired mice (a standard cholinergic amnesia model) showed reversal of memory deficits.
• Radial arm maze performance improved in some cohorts.

The models used are standard for preclinical cognitive research, and the results are internally consistent across the publication record. However, all available data comes from one primary research group, and rodent cognitive models have a poor track record of translating to human efficacy — particularly in Alzheimer's disease and other dementias, where dozens of promising preclinical compounds have failed in trials.

Neurodegeneration Models

Dihexa has been tested in rodent models of Alzheimer's-related pathology and ischemic brain injury:

• In models using amyloid-beta infusion or streptozotocin-induced neurodegeneration, Dihexa appeared to attenuate cognitive decline and reduce certain biomarkers of synaptic loss.
• In transient ischemia models, Dihexa showed neuroprotective effects when administered in proximity to the insult, likely through anti-apoptotic HGF/MET signalling.

These results are encouraging at the mechanistic level but do not constitute evidence of clinical efficacy.

Intranasal and Transdermal Delivery

One research interest has been non-injection delivery. Some data suggests Dihexa can cross the blood-brain barrier via intranasal administration — not surprising given its molecular weight (~520 Da) and lipophilic character. Transdermal patch formulations have been explored, but pharmacokinetic data from these routes in peer-reviewed literature is sparse. Much of the self-experimentation community data on this should be treated as anecdotal only.

Comparison to Related Nootropic Peptides

Semax and Selank have a clearer human evidence base, have been in clinical use in Eastern Europe for decades, and have more replicated research. Dihexa's potency claims are more dramatic but rest on a narrower and less independently replicated evidence base.

Research Limitations

No human clinical trial data. This is the central limitation. All of Dihexa's cognitive enhancement claims come from rodent models. The history of neuropharmacology is littered with compounds that replicated beautifully in animal models and failed to translate — including many HGF/MET-targeting approaches in oncology and neurology.

Single-group research origin. The published Dihexa literature is substantially concentrated in one research group at Washington State University. Independent replication of the core synaptogenesis and cognitive findings has not been prominently reported in peer-reviewed literature.

Pharmacokinetics poorly characterised. Human absorption, distribution, metabolism, and excretion (ADME) data are not publicly available. Optimal dosing, delivery route, and timing are unknown.

Long-term safety unknown. HGF/MET signalling has roles in tumour growth and metastasis. Chronic potentiation of this pathway carries theoretical oncogenic risk that would need careful evaluation in long-term safety studies — studies that have not been completed.

Regulatory status. Dihexa is not approved for human therapeutic use anywhere. It is available from research peptide suppliers as an unlicensed compound, with all the purity and quality-control concerns that implies.

Key Takeaways

1. Dihexa is an angiotensin IV-derived peptide that enhances HGF/MET receptor signalling, a pathway implicated in synapse formation and neuronal survival.
2. Animal model data shows significant cognitive improvements in aged rodents and models of neurodegeneration — results that are mechanistically plausible and internally consistent within the published literature.
3. The "10 million times more potent than BDNF" figure refers to a specific in vitro assay and should not be interpreted as a general statement about cognitive efficacy.
4. No human clinical trials have been completed. Translation from rodent cognition models to human benefit is highly uncertain.
5. The bulk of peer-reviewed research originates from a single group; independent replication is limited.
6. Long-term safety, particularly regarding HGF/MET's role in tumour biology, has not been evaluated in chronic administration studies.
7. Pharmacokinetic data in humans (bioavailability, dosing, delivery route) is not publicly available.
8. Dihexa remains a research compound with no approved therapeutic use. Researchers interested in the HGF/MET axis in cognition should monitor clinical trial registries for any emerging trials.

This article is for informational and research reference purposes only. Dihexa is not approved for human therapeutic use. It is a research compound intended for laboratory and preclinical research use only. Nothing in this article constitutes medical advice or endorsement of any particular use.